@DrLoomba gives #pegozafermin ENLIVEN study 48 week data.
⬇️ MRI-PDFF reduction across doses
⬇️ non invasive fibrosis markers
☠️ 4-6% TRAE leading to discontinuation. Mainly diarrhea and nausea. 1 SAE
ph3 ongoing to cirrhotic/non cirrhotic
#easlcongress #livertwitter

highlight of #EASLCongress was the ph2. presentation by ⁦@DrLoomba⁩ of #FGF21 #pegozafermin s/c every 2 weeks vs. placebo. Impressive data with ph3 to follo. Read the whole thing in today’s ⁦@NEJM⁩ ⁦@EASLnews⁩ ⁦@EASLedu⁩ https://dir.lat/ycH7DK